First-line eradication rates comparing two shortened non-bismuth quadruple regimens against<i>Helicobacter pylori</i>: an open-label, randomized, multicentre clinical trial

Abstract

Hybrid and concomitant regimens show good ER against H. pylori infection with an acceptable safety profile. They clearly displace OAC as first-line regimen in our area.